Roessig, Lothar

Vericiguat in patients with heart failure and reduced ejection fraction

Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., et al. (2020) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,358

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study

Pieske, B., Maggioni, A. P., Lam, C. S. P., Pieske-Kraigher, E., Filippatos, G., Butler, J., Ponikowski, P., Shah, S. J., Solomon, S. D., Scalise, A.-V., et al. (2017) · European Heart Journal

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 366

N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes

Ezekowitz, J. A., O’Connor, C. M., Troughton, R. W., Alemayehu, W. G., Westerhout, C. M., Voors, A. A., Butler, J., Lam, C. S. P., Ponikowski, P., Emdin, M., et al. (2020) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiac Fibrosis and Remodeling

Cited by 146

Patient selection in heart failure with preserved ejection fraction clinical trials

Kelly, J. P., Mentz, R. J., Mebazaa, A., Voors, A. A., Butler, J., Roessig, L., Fiuzat, M., Zannad, F., Pitt, B., O’Connor, C. M., et al. (2015) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 139